Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
Sponsor: CRISPR Therapeutics AG
Summary
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.
Official title: A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed or Refractory Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
19
Start Date
2023-03-13
Completion Date
2025-09-18
Last Updated
2026-11-05
Healthy Volunteers
No
Conditions
Interventions
CTX131
CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)
Locations (7)
Research Site 3
Duarte, California, United States
Research Site 7
Chicago, Illinois, United States
Research Site 6
Boston, Massachusetts, United States
Research Site 2
St Louis, Missouri, United States
Research Site 4
Durham, North Carolina, United States
Research Site 1
Nashville, Tennessee, United States
Research Site 5
Houston, Texas, United States